• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Risk management plans in EU and EAEU

09.04.2018/in News /by X7 Research

According to the European Medicines Agency (EMA) requirements, pharmaceutical companies should provide a risk management plan (RMP) when they apply for a marketing authorization. To simplify this task, EMA has published a guidance on how to develop RMPs in 2012 along with the RMP template.

Therefore, RMPs must contain the following information:

  • safety profile of the drug;
  • how potential risks for patients associated with this drug will be prevented or mitigated;
  • strategies for further trials or other activities with the aim of getting more information on safety and efficacy profiles of this drug;
  • how to measure the usefulness of measures taken to minimize potential risks.

In accordance with the European Union requirements, pharmaceutical companies must provide a risk management plan at the same time as applying for marketing authorization. However, if the drug does not have a RMP, the authority may require submitting it when a market authorization holder will apply for adding significant alterations in the marketing authorization. Moreover, if the medicinal product is nationally authorized a national competent authority in the European Union may make a query and demand RMP in case a concern regarding the benefit-risk balance for this drug arises.

EMA issued the second version of the RMP template on 30 March 2017. Marketing authorization holders and applicants may use this template for submitting RMPs since 31 March 2017. However, all marketing authorization holders and applicants are obligated to use it since 31 March 2018.

“Rules of good pharmacovigilance practice of Eurasian European Union” approved by the Decision of the Board of Eurasian European Committee dated 03 Nov 2016 # 87, assumes the use of the RMP template that is maximally harmonized with EMA RMP template issued in 2012.

At the same time, EMA has published the second version of RMP template in 2017 that is substantially different from the version issued in 2012, and corresponding recommendations, that marketing authorization holders and applicants could use when submitting the RMP since 31 Mar 2018, yet, it was on the applicant’s discretion whether to use the old or the new template.

Since 31 Mar 2018, the use of the new RMP template for EU submissions became mandatory, and this creates additional complications for the companies that submit both in EU and EAEU, as substantially different templates are to be used in corresponding regions.

Source: EMA.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

2 + 2 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
X7 Research will take part in IPhEB Russia Quality control of biomedical cellular products
Scroll to top